Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417894 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2183805 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL16342359 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2037115 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL16323109 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL25176741 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL414546 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL2182221 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL20897215 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 | |
| SCHEMBL28595399 | 1.00 | TSHR (0.52) | TSHRLMNANFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583900-B2 | Peptide conjugates and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2026-03-24 | — | — | US | disclosed |
| US-20250325683-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | SCRIPPS RESEARCH INST (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250320252-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | SCRIPPS RESEARCH INST (US) | 2025-10-16 | — | — | US | disclosed |
| US-12329823-B2 | Long-acting dual GIP/GLP-1 peptide conjugates and methods of use | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025054459-A1 | RNAI OLIGONUCLEOTIDE CONJUGATES | DICERNA PHARMACEUTICALS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024232593-A1 | METHOD FOR PREPARING MONO-TERT-BUTYL-ESTERIFIED SATURATED HYDROCARBON, AND CYCLIC PREPARATION METHOD THEREFOR | 주식회사 아미노로직스 | 2024-11-14 | — | — | WO | disclosed |
| US-20240148884-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | THE SCRIPPS RESEARCH INSTITUTE | 2024-05-09 | — | — | US | disclosed |
| EP-4352088-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | The Scripps Research Institute (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117794946-A | Long acting dual GIP/GLP-1 peptide conjugates and methods of use | 斯克利普斯研究所 | 2024-03-29 | — | — | CN | disclosed |
| CN-114685646-B | Preparation method and application of polypeptide side chain analogue | 厦门赛诺邦格生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| US-8067362-B2 | Antidiabetic agents; genetic engineered polypeptide; having a side chain attached alpha -amino group of the N-terminal amino acid of the B chain via an amide bond, with free carboxylic acid group, a fatty acid; soluble at physiological pH, prolonged profile of action; hypoglycemic agents | NOVO NORDISK AS (DK) | 2011-11-29 | — | — | US | disclosed |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | NOVO NORDISK A/S (DK) | 2011-05-05 | — | — | US | disclosed |
| CN-102037008-A | Protease stabilized, acylated insulin analogues | NOVO NORDISK AS | 2011-04-27 | — | — | CN | disclosed |
| EP-2256130-A1 | Novel insulin derivatives | Novo Nordisk A/S (DK) | 2010-12-01 | — | — | EP | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| US-20080076705-A1 | Insulin Derivatives | NOVO NORDISK A/S (DK) | 2008-03-27 | — | — | US | disclosed |
| EP-1846446-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006082204-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148884-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | GLP1R, GIPR, GCGR | TSHR 142/4885LMNA 4176/4885NFKB1 4546/4885 |
| US-20110105720-A1 | PROTEASE STABILIZED, ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | TSHR 819/4885LMNA 1619/4885NFKB1 2666/4885 |
| US-12583900-B2 | Peptide conjugates and methods of use | GIPR, GLP1R, GCG | TSHR 15/4885LMNA 3974/4885NFKB1 4818/4885 |
| US-20080076705-A1 | Insulin Derivatives | IAPP, INSR, GPR119 | TSHR 597/4885LMNA 430/4885NFKB1 1361/4885 |
| US-20250325683-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | GLP1R, GIPR, GCGR | TSHR 142/4885LMNA 4176/4885NFKB1 4546/4885 |
| US-12329823-B2 | Long-acting dual GIP/GLP-1 peptide conjugates and methods of use | GLP1R, GIPR, GCGR | TSHR 142/4885LMNA 4176/4885NFKB1 4546/4885 |
| US-20250320252-A1 | LONG-ACTING DUAL GIP/GLP-1 PEPTIDE CONJUGATES AND METHODS OF USE | GLP1R, GIPR, GCGR | TSHR 142/4885LMNA 4176/4885NFKB1 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.